GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Neumora Therapeutics Inc (NAS:NMRA) » Definitions » Price-to-Free-Cash-Flow

Neumora Therapeutics (Neumora Therapeutics) Price-to-Free-Cash-Flow : N/A (As of Jun. 04, 2024)


View and export this data going back to 2023. Start your Free Trial

What is Neumora Therapeutics Price-to-Free-Cash-Flow?

As of today (2024-06-04), Neumora Therapeutics's share price is $9.79. Neumora Therapeutics's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2024 was $-1.82. Hence, Neumora Therapeutics's Price-to-Free-Cash-Flow Ratio for today is N/A.

The historical rank and industry rank for Neumora Therapeutics's Price-to-Free-Cash-Flow or its related term are showing as below:

NMRA's Price-to-Free-Cash-Flow is not ranked *
in the Biotechnology industry.
Industry Median: 31.04
* Ranked among companies with meaningful Price-to-Free-Cash-Flow only.

Neumora Therapeutics's Free Cash Flow per Share for the three months ended in Mar. 2024 was $-0.27. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was $-1.82.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was -138.60% per year.

During the past 5 years, Neumora Therapeutics's highest 3-Year average Free Cash Flow per Share Growth Rate was -138.60% per year. The lowest was -138.60% per year. And the median was -138.60% per year.


Neumora Therapeutics Price-to-Free-Cash-Flow Historical Data

The historical data trend for Neumora Therapeutics's Price-to-Free-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Neumora Therapeutics Price-to-Free-Cash-Flow Chart

Neumora Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Free-Cash-Flow
- - - - -

Neumora Therapeutics Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Price-to-Free-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Neumora Therapeutics's Price-to-Free-Cash-Flow

For the Biotechnology subindustry, Neumora Therapeutics's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Neumora Therapeutics's Price-to-Free-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Neumora Therapeutics's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Neumora Therapeutics's Price-to-Free-Cash-Flow falls into.



Neumora Therapeutics Price-to-Free-Cash-Flow Calculation

Neumora Therapeutics's Price-to-Free-Cash-Flow ratio for today is calculated as

Price-to-Free-Cash-Flow Ratio=Share Price/ Free Cash Flow per Share (TTM)
=9.79/-1.824
=N/A

Neumora Therapeutics's Share Price of today is $9.79.
Neumora Therapeutics's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.82.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Price-to-Free-Cash-Flow Ratio=Market Cap/Free Cash Flow

Neumora Therapeutics  (NAS:NMRA) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.


Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.


Neumora Therapeutics Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Neumora Therapeutics's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Neumora Therapeutics (Neumora Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
490 Arsenal Way, Suite 200, Watertown, MA, USA, 02472
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the global brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has rapidly scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. The company expects to continue to progress in the development of its pipeline with the planned initiation of multiple clinical trials across its programs over the next 12 to 18 months, which supports numerous anticipated data readouts.
Executives
Kristina Burow director, 10 percent owner 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Arch Venture Partners Xii, Llc 10 percent owner 8755 W HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Arch Venture Partners X, Llc 10 percent owner 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Henry O Gosebruch director, officer: President & CEO 1 N. WAUKEGAN ROAD, NORTH CHICAGO IL 60064-6092
Arch Venture Fund X, L.p. 10 percent owner 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Amgen Inc 10 percent owner ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320
Arch Venture Partners X Overage, L.p. 10 percent owner 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Arch Venture Partners Viii, Llc 10 percent owner 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Arch Venture Partners X, L.p. 10 percent owner 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Daljit Singh Aurora officer: Chief Strategy Officer C/O DERMIRA, INC., 275 MIDDLEFIELD ROAD, SUITE 150, MENLO PARK CA 94025
Arch Venture Fund Xii, L.p. 10 percent owner 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Arch Venture Partners Xii, L.p. 10 percent owner 8755 W HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Joshua Pinto officer: Chief Financial Officer C/O NEUMORA THERAPEUTICS, INC., 490 ARSENAL WAY, SUITE 200, WATERTOWN MA 02472
Alaa Halawa director C/O NEUMORA THERAPEUTICS, INC., 490 ARSENAL WAY, SUITE 200, WATERTOWN MA 02472
Carol Y. Suh officer: Chief Operating Officer C/O NEUMORA THERAPEUTICS, INC., 490 ARSENAL WAY, SUITE 200, WATERTOWN MA 02472